Table 3.
Molecular marker expression at baseline, 8 wk, and at either of these time points in the overall study population and according to benefit and resistance
| Patients, no./total evaluable (%) | p value | ||||||
|---|---|---|---|---|---|---|---|
| Primary resistance |
Moderate benefit 4–6 mo |
Prolonged benefit >6 mo |
Benefit | All patients | Primary resistant vs benefit |
Primary resistant vs prolonged benefit |
|
| Molecular marker expression (baseline) | |||||||
| Combined androgen signaling signature | 3/12 (25) | 4/6 (67) | 6/6 (100) | 10/12 (83) | 13/24 (54) | 0.012 | 0.009 |
| N-terminal AR overexpression (>75% expression plus high intensity) | 8/13 (62) | 5/6 (83) | 6/6 (100) | 11/12 (92) | 19/25 (76) | 0.2 | 0.1 |
| CYP17 presence (>10% expression) | 5/12 (42) | 4/6 (67) | 6/6 (100) | 10/12 (83) | 15/24 (62) | 0.09 | 0.038 |
| ARV7 presence | 6/12 (50) | 1/6 (17) | 0/5 (0) | 1/11 (9) | 6/23 (26) | 0.07 | 0.1 |
| ERG presence | 1/11 (9) | 2/6 (33) | 2/5 (40) | 4/11 (36) | 5/22 (23) | 0.3 | 0.2 |
| GR presence | 5/13 (38) | 2/5 (40) | 1/6 (17) | 3/11 (27) | 8/24 (33) | 0.68 | 0.6 |
| Ki67 (>30% expression) | 9/12 (75) | 2/5 (40) | 1/6 (17) | 3/11 (27) | 12/23 (52) | 0.039 | 0.043 |
| Phospho-Src (>30%) | 12/13 (92) | 4/5 (80) | 2/5 (40) | 6/10 (60) | 18/23 (78) | 0.1 | 0.044 |
| Phospho-Met (>30%) | 10/11 (91) | 2/5 (40) | 3/5 (60) | 5/10 (50) | 15/21 (71) | 0.06 | 0.21 |
| Molecular marker expression (week 8) | |||||||
| N-terminal AR overexpression | 8/11 (73) | 5/6 (83) | 4/7 (57) | 9/13 (69) | 17/24 (71) | 1 | 0.6 |
| CYP17 presence (>10% expression) | 6/10 (60) | 3/6 (50) | 4/6 (67) | 7/12 (58) | 13/22 (59) | 1 | 1 |
| ARV7 presence | 7/10 (70) | 2/6 (33) | 0/7 (0) | 2/13 (15) | 9/23 (39) | 0.013 | 0.01 |
| ERG presence | 1/9 (11) | 1/5 (20) | 2/3 (67) | 3/8 (38) | 4/17 (24) | 0.3 | 0.1 |
| GR presence | 6/9 (67) | 2/6 (33) | 1/6 (17) | 3/12 (25) | 9/21 (43) | 0.09 | 0.12 |
| Ki67 (>30%) | 5/11 (45) | 1/6 (17) | 0/5 (0) | 1/11 (9) | 6/22 (27) | 0.2 | 0.1 |
| Phospho-Src (>30%) | 10/11 (91) | 6/6 (100) | 2/6 (33) | 8/12 (67) | 18/23 (78) | 0.3 | 0.028 |
| Phospho-Met (>30%) | 6/9 (67) | 4/5 (80) | 2/5 (40) | 6/10 (60) | 12/19 (63) | 1 | 0.6 |
| Molecular marker expression (any time point) | |||||||
| ARV7 presence* | 8/14 (57) | 3/7 (43) | 0/7 (0) | 3/14 (21) | 11/28 (39) | 0.1 | 0.018 |
| ERG (presence)* | 1/12 (8) | 3/7 (43) | 3/7 (43) | 6/14 (43) | 7/26 (27) | 0∙08 | 0.1 |
| GR (presence)* | 9/13 (69) | 4/7 (57) | 2/7 (29) | 6/14 (43) | 15/27 (56) | 0.3 | 0.2 |
| Ki67 (>30%)** | 10/14 (71) | 3/7 (43) | 1/8 (12) | 4/15 (27) | 14/29 (48) | 0.027 | 0.024 |
| Phospho-Src (>30%)** | 12/13 (92) | 4/6 (67) | 2/7 (29) | 6/13 (46) | 18/26 (69) | 0.03 | 0.007 |
| Phospho-met (>30%)** | 11/13 (85) | 4/7 (57) | 4/7(57) | 8/14 (57) | 19/27 (70) | 0.1 | 0.3 |
AR = androgen receptor; GR = glucocorticoid receptor.
*
Any time point with presence (>5–10% tumor cell expression).
**
Any time point with >30% expression.